Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease

OBJECTIVE: The aim of this study was to assess the budget impact of introducing the proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) alirocumab and evolocumab to market for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallya, Usha G., Boklage, Susan H., Koren, Andrew, Delea, Thomas E., Mullins, C. Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775395/
https://www.ncbi.nlm.nih.gov/pubmed/29181773
http://dx.doi.org/10.1007/s40273-017-0590-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775395/
https://www.ncbi.nlm.nih.gov/pubmed/29181773
http://dx.doi.org/10.1007/s40273-017-0590-5

Ejemplares similares